Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 1
2006 1
2007 2
2008 4
2009 4
2010 4
2011 2
2013 4
2014 4
2015 5
2016 4
2017 4
2018 1
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

38 results
Results by year
Filters applied: . Clear all
Page 1
Type 2 diabetes mellitus.
DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R. DeFronzo RA, et al. Nat Rev Dis Primers. 2015 Jul 23;1:15019. doi: 10.1038/nrdp.2015.19. Nat Rev Dis Primers. 2015. PMID: 27189025 Review.
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.
DeFronzo RA. DeFronzo RA. Diabetes Obes Metab. 2017 Oct;19(10):1353-1362. doi: 10.1111/dom.12982. Epub 2017 Jun 7. Diabetes Obes Metab. 2017. PMID: 28432726 Free PMC article. Review.
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.
Di Pino A, DeFronzo RA. Di Pino A, et al. Endocr Rev. 2019 Dec 1;40(6):1447-1467. doi: 10.1210/er.2018-00141. Endocr Rev. 2019. PMID: 31050706 Free PMC article. Review.
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA. Merovci A, et al. J Clin Invest. 2014 Feb;124(2):509-14. doi: 10.1172/JCI70704. Epub 2014 Jan 27. J Clin Invest. 2014. PMID: 24463448 Free PMC article. Clinical Trial.
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. Abdul-Ghani M, et al. Diabetes Care. 2016 May;39(5):717-25. doi: 10.2337/dc16-0041. Diabetes Care. 2016. PMID: 27208375 Free PMC article. Clinical Trial.
Dapagliflozin lowers plasma glucose concentration and improves β-cell function.
Merovci A, Mari A, Solis-Herrera C, Xiong J, Daniele G, Chavez-Velazquez A, Tripathy D, Urban McCarthy S, Abdul-Ghani M, DeFronzo RA. Merovci A, et al. J Clin Endocrinol Metab. 2015 May;100(5):1927-32. doi: 10.1210/jc.2014-3472. Epub 2015 Feb 24. J Clin Endocrinol Metab. 2015. PMID: 25710563 Free PMC article. Clinical Trial.
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D, DeFronzo RA, Norton L, Abdul-Ghani M. Daniele G, et al. Diabetes Care. 2016 Nov;39(11):2036-2041. doi: 10.2337/dc15-2688. Epub 2016 Aug 25. Diabetes Care. 2016. PMID: 27561923 Free PMC article. Clinical Trial.
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Abdul-Ghani M, et al. Diabetes Care. 2017 Jul;40(7):813-820. doi: 10.2337/dc16-2736. Diabetes Care. 2017. PMID: 28637886 Free PMC article.
Dapagliflozin for the treatment of type 2 diabetes.
Abdul-Ghani MA, DeFronzo RA. Abdul-Ghani MA, et al. Expert Opin Pharmacother. 2013 Aug;14(12):1695-703. doi: 10.1517/14656566.2013.812632. Epub 2013 Jun 26. Expert Opin Pharmacother. 2013. PMID: 23800130 Free PMC article. Review.
Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport.
Abdul-Ghani MA, DeFronzo RA. Abdul-Ghani MA, et al. J Intern Med. 2014 Oct;276(4):352-63. doi: 10.1111/joim.12244. J Intern Med. 2014. PMID: 24690096 Free PMC article. Review.
38 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback